Alterations of lipolytic enzymes and high-density lipoprotein subfractions induced by physical activity in type 2 diabetes mellitus.
OBJECTIVE
This study investigates the effects of regular moderate physical activity on lipolytic enzymes and plasma lipid concentration, particularly high-density lipoprotein cholesterol (HDL-C) subfractions, in patients with type 2 diabetes mellitus.


METHODS
Ten patients participated in a 3-month exercise programme without any changes in current medical therapy. The control group consisted of six patients who were matched with regard to sex, age, diabetes duration and diabetes therapy.


RESULTS
Mean (+/- SE) physical activity in the intervention group increased from 70 +/- 21 to 220 +/- 28 min per week, which resulted in an increase in total HDL-C from 1.04 +/- 0.07 to 1.28 +/- 0.12 (P < 0.001). The HDL3-C subfraction increased from 0.71 +/- 0.08 to 0.86 +/- 0.08 mM (P = 0.01) with no significant changes in the HDL2-C subfraction (0.33 +/- 0.04 vs. 0.42 +/- 0.05). These changes were paralleled by an 85% increase in hepatic lipase (HL) activity, from 25.7 +/- 5.1 to 47.4 +/- 4.9 micromol x mL(-1) x h(-1) (P < 0.001) and a 45% increase in lipoprotein lipase (LPL) activity, from 16.8 +/- 3.0-24.3 +/- 2.7 micromol x mL(-1) x h(-1) (P = 0.01). Lecithin-cholesterol acyl-transferase (LCAT) activity increased by 32%, from 156 +/- 26 to 206 +/- 32 nmol x mL(-1) x h(-1) (P < 0.001). In the control group there were no significant changes in any of the variables assessed.


CONCLUSIONS
Regular moderate physical activity in patients with type 2 diabetes led to an overall increase in HL, LPL, and LCAT. HL showed a more pronounced increase than LPL and LCAT. The changes in lipolytic and transferase enzyme pattern resulted in a significant increase of plasma HDL-C, mainly of the HDL3-C subfraction.
Lehmann
R
R
Department of Internal Medicine, University Hospital Zürich, Switzerland. Roger.Lehmann@dim.usz.ch
Engler
H
H
Honegger
R
R
Riesen
W
W
Spinas
G A
GA
D000328:Adult; D000368:Aged; D000925:Anticoagulants; D016632:Apolipoprotein A-I / Q000097:blood; D001786:Blood Glucose; D001823:Body Composition; D003924:Diabetes Mellitus, Type 2 / Q000378:metabolism*; D015444:Exercise; D005260:Female; D006493:Heparin; D006801:Humans; D007333:Insulin Resistance; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008075:Lipoproteins, HDL / Q000097:blood*; D008099:Liver / Q000201:enzymology; D008297:Male; D008875:Middle Aged; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood
D000925:Anticoagulants; D016632:Apolipoprotein A-I; D001786:Blood Glucose; D008075:Lipoproteins, HDL; D014280:Triglycerides; D006493:Heparin; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D008071:Lipoprotein Lipase